Disfibrinogenemiya and Hidden Hemolysis - Indicators of Hemorrhagic Syndrome in Erysipelas

Elena. G. Fokina

Authors

Elena. G. Fokina

Keywords:

facial erysipelas, lower-limb erysipelas, hidden hemolysis, DIC-like syndrome, erythrocyte aggregation, platelet aggregation, fibrinogen, D-dimer, pro

Abstract

Abstract not found

Downloads

How to Cite

Disfibrinogenemiya and Hidden Hemolysis - Indicators of Hemorrhagic Syndrome in Erysipelas. (2016). Global Journal of Medical Research, 16(8), 1-11. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

E. Fokina, I. Rosly, S. Potekaeva (2014) Laboratory evaluation of erysipelatous imflammation. 1, 28-32.

Martin Denis F, Ploy M.C (2001) Erysipelas: microbiological and pathogenic data. 128, 317-326.

S. Morozova, A. Timurzieva (2015) Professional view of the problem of external otitis. 3, 8-11.

A. Frolov (2003) Etiopathgenetic particularities of the development of necrotic form of erysipelas, its prediction and principles of complex therapy// Synopsis of PhD thesis.

M. Mitrofanova, Yu (2010) Disturbances of hemostasis and vascular endothelial function in patients with erysipelas// Synopsis of PhD thesis.

Sheremetiev Yu, G. Makin, F. Suslov, Yu (1995) A method for the registration of the changes of surface erythrocyte charge (lanthanum chloride)// Federal Service for Intellectual Property.

Papachristodoulou D., Snape A., Elliott W.H., Elliott D.C. (2014) Biochemistry and Molecular Biology. 5, 592.

E. Fokina (2014) Some particularities of primary erysipelas under present-day conditions.// Terapevtichesky arkhiv (Therapeutic archives) Moscow-2014. 11, 70-77.

F. Castellino, V. Ploplis (2009) The protein C pathway and pathologic processes // J Throm Haemost. 7(1), 140-145. https://doi.org/10.1111/j.1538-7836.2009.03410.x

B. Dahlback (1997) Resistance to activated protein C as risk factor for thrombosis: molecular mechanism, laboratory investigation and clinical managements. 34(3), 217-234.

Charles Esmon (2001) Role of coagulation inhibitors in inflammation Thromb Haemost. 86(07), 51-56. https://doi.org/10.1055/s-0037-1616200

Ratnikova L.I, Dubovikova T.A (2012) Evaluation of the state of vascular platelet hemostasis in patients with hemorrhagic forms of erysipelas// Zhurnal infectologii (Journal of Infectology). 4(1), 53-57.

L. Bockeria, L. Klimovich, A. Potekhina (2004) Mechanisms of coagulation inhibitors involvement into the development of inflammatory reaction and perspective trends of anticoagulation therapy// Klinicheskaya fisiologia krovoobraschenia. 1, 46-55.

Bernard G.R, Vincent J.L (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med. 344(10), 699-709. https://doi.org/10.1056/nejm200103083441001

Shaun Coughlin (2001) Protease-activated receptors in vascular biology Thromb Haemost. 86(07), 298-307. https://doi.org/10.1055/s-0037-1616227

Esmon C.T, Taylor F.B (1991) Inflammation and Coagulation: Linked Processes Potentially Regulated Through a Common Pathway Mediated by Protein C. 66(01), 160-165. https://doi.org/10.1055/s-0038-1646385

D. Chen, A. Dorling (2009) Dorling A Critical roles for thrombin in acute and chronic inflammation // J Throm Haemost. 7(1), 122-126. https://doi.org/10.1111/j.1538-7836.2009.03413.x

Prasanna Sridharan, Ronald Chamberlain (2013) The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills? Surg Infect (Larchmt). 14(6), 489-511. https://doi.org/10.1089/sur.2012.028

B. Kile (2009) The role of the intrinsic apoptosis pathway in platelet life and death // J Throm Haemost. 7(1), 214-217. https://doi.org/10.1111/j.1538-7836.2009.03366.x